Respira appoints new CEO to drive inhalable therapeutics  

New appointment

Clinical-stage company Respira Technologies has appointed a new Chief Executive Officer (CEO) to the company. 

Brian Quigley will take over as CEO after working as Respira’s Chief Operating Officer (COO) for the past two years.  

Quigley previously worked at Altria Group for 16 years where he spent seven years as President & CEO at Altria’s Smokeless and Innovative Products/Vapor Businesses.  

Respira is currently developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases. The company is in the midst of securing financing for clinical trials. It’s hoped that Quigley’s background as a successful business leader and Fortune 150 CEO in the space will help drive Respira to its next phase as it advances to clinical trials. 

Respira’s founder, Mario Danek, will transition to the role of Chief Technology Officer (CTO). In this role, Danek will focus on concentrating on inventing and refining its innovative inhalation device across multiple potential indication areas and target markets.  

Respira is now attempting to gain a combination product authorisation from the FDA for the first inhalable prescription smoking cessation therapy. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free